首页> 外文期刊>South African medical journal: Suid-Afrikaanse tydskrif vir geneeskunde >Oral chlorhexidine in the prevention of ventilator-associated pneumonia in critically ill adults in the ICU: A systematic review
【24h】

Oral chlorhexidine in the prevention of ventilator-associated pneumonia in critically ill adults in the ICU: A systematic review

机译:口服洗必泰在ICU中预防危重症患者的呼吸机相关性肺炎:系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose. The aim of this review was to evaluate the evidence on the effectiveness of oral chlorhexidine in the prevention of ventilator-associated pneumonia (VAP) in critically ill adult mechanically ventilated patients in intensive care units (ICUs).Methodology. An extensive literature search of studies published in English was undertaken between June 2010 and June 2011. Electronic databases searched were the Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index of Nursing and Allied Health (CINAHL) and MEDLINE. Reference lists of articles, textbooks and conference summaries were examined and hand searching was performed. Literature searches were done using the following Medical Subject Headings (MeSH) terms: ventilator-associated pneumonia, VAP, chlorhexidine, hospital-acquired pneumonia, nosocomial infections, mechanically ventilated patients, intensive care, mouthwash, mouth care, oral care, oral hygiene and dental care.Selection criteria. Two reviewers selected the studies independently. Eight randomised controlled trials investigating the efficacy of oral chlorhexidine versus power tooth brushing, Listerine, placebos, bicarbonate isotonic serum rinse and normal saline in the prevention of VAP in adult mechanically ventilated, critically ill patients in ICUs met the inclusion criteria.Data collection and analysis. All relevant data were entered into Review Manager (version 5.1) for analyses. The effect measure of choice was the risk ratio (RR) with 95% confidence intervals (CIs) for dichotomous data using the random effects (Mantel-Haenszel) model (p-value 0.05). Heterogeneity was assessed using the Cochrane Q statistic and I2.Results. Eight randomised controlled trials met the inclusion criteria for this review. There was a 36% higher chance of VAP in the control group compared with the chlorexidine group (RR 0.64, 95% CI 0.44 - 0.91). The variation between the included studies was very small (X~2=0.24).Conclusion. Treatment with chlorhexidine decreased the risk of VAP by 36%. The use of 2% chlorhexidine may be most effective in reducing the incidence of VAP. There was no evidence of an effect of chlorhexidine on mortality.
机译:目的。这篇综述的目的是评估在重症监护病房(ICU)中危重成人机械通气患者中口服洗必泰在预防呼吸机相关性肺炎(VAP)方面的证据。在2010年6月至2011年6月之间,对以英语发表的研究进行了广泛的文献检索。检索的电子数据库为Cochrane对照试验中央登记册(CENTRAL),护理和专职医疗累积指数(CINAHL)和MEDLINE。检查了文章,教科书和会议摘要的参考清单,并进行了手工搜索。使用以下医学主题词(MeSH)术语进行文献检索:呼吸机相关性肺炎,VAP,洗必泰,医院获得性肺炎,医院感染,机械通气患者,重症监护,漱口水,口腔护理,口腔护理,口腔卫生和牙科保健。选择标准。两名评论者独立选择了研究。八项随机对照试验研究了口服洗必泰与电动刷牙,李斯特菌素,安慰剂,碳酸氢盐等渗血清冲洗液和生理盐水在ICU的成人机械通气危重患者中预防VAP的疗效符合纳入标准。数据收集和分析。所有相关数据都输入到Review Manager(5.1版)中进行分析。选择的效果量度是使用随机效果(Mantel-Haenszel)模型(p值0.05)时二分数据的风险比(RR)和95%置信区间(CIs)。使用Cochrane Q统计量和I2。结果评估异质性。八项随机对照试验符合该评价的纳入标准。与氯己定组相比,对照组中VAP的几率高出36%(RR 0.64,95%CI 0.44-0.91)。纳入研究之间的差异很小(X〜2 = 0.24)。洗必泰治疗可使VAP风险降低36%。使用2%的洗必泰可能会最有效地降低VAP的发生率。没有证据表明洗必太对死亡率有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号